Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients
with coronary artery disease, and an even higher proportion of those with heart failure (HF) …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a …

Background Various types of pulmonary diseases are associated with iron deficiency.
However, information on iron status in coronavirus disease 2019 (COVID-19) is scarce …

Pulmonary hypertension (PH) is a feature of a variety of diseases and continues to harbor
high morbidity and mortality. The main consequence of PH is right-sided heart failure which …

Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Pulmonary hypertension (PH) is a heterogeneous and fatal disease of the lung vasculature,
where metabolic and mitochondrial dysfunction may drive pathogenesis. Similar to the …

Pulmonary arterial hypertension (PAH) is a devastating disease that is precipitated by
hypertrophic pulmonary vascular remodeling of distal arterioles to increase pulmonary artery …

Iron is essential for many biological processes. Inadequate or excess amount of body iron
can result in various pathological consequences. The pathological roles of iron in …